LimmaTech Biologics Funding: $37M Raised, Series A (2023)
LimmaTech Biologics is based in Schlieren, Switzerland. It has raised $37M in total funding. Latest round: Series A.
LimmaTech Biologics funding overview
LimmaTech Biologics is based in Schlieren, Switzerland. LimmaTech Biologics has raised $37M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series A announced in October 2023. The round record for LimmaTech Biologics runs through 2023; nothing later has been disclosed. Investors on record include Adjuvant Capital, AXA IM Alts, Novo Holdings REPAIR Impact Fund. 3 distinct backers are named across the disclosed rounds.
LimmaTech Biologics at a glance
Total raised
$37M
Latest round
Series A
Latest round date
October 2023
Headquarters
Schlieren, Switzerland
Notable investors
Adjuvant Capital, AXA IM Alts, Novo Holdings REPAIR Impact Fund
Frequently asked about LimmaTech Biologics funding
How much has LimmaTech Biologics raised?
LimmaTech Biologics has raised $37M in total disclosed funding across the rounds on record.
Who has invested in LimmaTech Biologics?
Adjuvant Capital, AXA IM Alts, Novo Holdings REPAIR Impact Fund are named among the investors backing LimmaTech Biologics.
What was the latest LimmaTech Biologics funding round?
The most recent disclosed round is a Series A, announced in October 2023.
Where is LimmaTech Biologics based?
LimmaTech Biologics is based in Schlieren, Switzerland.
When did LimmaTech Biologics last raise?
The last disclosed LimmaTech Biologics round closed in October 2023 at Series A.
LimmaTech Biologics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in Schlieren below to benchmark round size and investor mix.
